Matches in SemOpenAlex for { <https://semopenalex.org/work/W2766321881> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2766321881 endingPage "ix22" @default.
- W2766321881 startingPage "ix22" @default.
- W2766321881 abstract "Many clinical trials with new drugs for unresectable gastric cancer has been globally conducted. Although barriers in global development from investigators' point of view do exist, some were overcome and some have been still issues. Drug-specific issues should be considered such as pharmacogenomics evaluation. For example, in Asian populations where the frequency of UGT1A1*28 is low, other UGT1A1 variants can also play a role in irinotecan toxicity: in a Japanese study, two haplotype (*28 containing the UGT1A1*28 allele and *6 containing the exon 1 G71R polymorphism) groups were associated with reduced area under the curve (AUC) ratios of SN-38G to SN-38, which is predicted to have an effect on irinotecan toxicity. Patients with one *6 haplotype and one *28 haplotype had significantly lower AUC ratios compared with patients with homozygous wild-type UGT1A1. Difference in clinical practice has been a common problem when planning global studies. In AVAGAST study, which compared XP vs XP+bevacizumab in the 1st-line setting, HR in OS was 0.63 in Pan-America and 0.97 in Asia. These differences may come from the differences in proportion of 2nd-line treatment and proportion of minimal peritoneal metastasis. Such experiences have been utilized into planning and conducting subsequent global trials in gastric cancer. On the other hand, in Asia, especially in Japan, specific development for patients with peritoneal metastasis have been conducted. Now, however, only patients with severe peritoneal metastasis are excluded from the standard development strategy, there are no conflicts with global development. Totally, Asian trials can be performed without difficulties, and there are some issues to consider to plan and conduct global trials." @default.
- W2766321881 created "2017-11-10" @default.
- W2766321881 creator A5013766133 @default.
- W2766321881 date "2017-10-01" @default.
- W2766321881 modified "2023-09-26" @default.
- W2766321881 title "Development of new agents for unresectable gastric cancer: Global? Asian? Japanese?" @default.
- W2766321881 doi "https://doi.org/10.1093/annonc/mdx554.002" @default.
- W2766321881 hasPublicationYear "2017" @default.
- W2766321881 type Work @default.
- W2766321881 sameAs 2766321881 @default.
- W2766321881 citedByCount "0" @default.
- W2766321881 crossrefType "journal-article" @default.
- W2766321881 hasAuthorship W2766321881A5013766133 @default.
- W2766321881 hasBestOaLocation W27663218811 @default.
- W2766321881 hasConcept C104317684 @default.
- W2766321881 hasConcept C121608353 @default.
- W2766321881 hasConcept C126322002 @default.
- W2766321881 hasConcept C143998085 @default.
- W2766321881 hasConcept C170734499 @default.
- W2766321881 hasConcept C180754005 @default.
- W2766321881 hasConcept C197754878 @default.
- W2766321881 hasConcept C2776694085 @default.
- W2766321881 hasConcept C2777802072 @default.
- W2766321881 hasConcept C2779013556 @default.
- W2766321881 hasConcept C2780035454 @default.
- W2766321881 hasConcept C2780259306 @default.
- W2766321881 hasConcept C526805850 @default.
- W2766321881 hasConcept C54355233 @default.
- W2766321881 hasConcept C64903051 @default.
- W2766321881 hasConcept C71924100 @default.
- W2766321881 hasConcept C86803240 @default.
- W2766321881 hasConcept C90924648 @default.
- W2766321881 hasConcept C98274493 @default.
- W2766321881 hasConceptScore W2766321881C104317684 @default.
- W2766321881 hasConceptScore W2766321881C121608353 @default.
- W2766321881 hasConceptScore W2766321881C126322002 @default.
- W2766321881 hasConceptScore W2766321881C143998085 @default.
- W2766321881 hasConceptScore W2766321881C170734499 @default.
- W2766321881 hasConceptScore W2766321881C180754005 @default.
- W2766321881 hasConceptScore W2766321881C197754878 @default.
- W2766321881 hasConceptScore W2766321881C2776694085 @default.
- W2766321881 hasConceptScore W2766321881C2777802072 @default.
- W2766321881 hasConceptScore W2766321881C2779013556 @default.
- W2766321881 hasConceptScore W2766321881C2780035454 @default.
- W2766321881 hasConceptScore W2766321881C2780259306 @default.
- W2766321881 hasConceptScore W2766321881C526805850 @default.
- W2766321881 hasConceptScore W2766321881C54355233 @default.
- W2766321881 hasConceptScore W2766321881C64903051 @default.
- W2766321881 hasConceptScore W2766321881C71924100 @default.
- W2766321881 hasConceptScore W2766321881C86803240 @default.
- W2766321881 hasConceptScore W2766321881C90924648 @default.
- W2766321881 hasConceptScore W2766321881C98274493 @default.
- W2766321881 hasLocation W27663218811 @default.
- W2766321881 hasOpenAccess W2766321881 @default.
- W2766321881 hasPrimaryLocation W27663218811 @default.
- W2766321881 hasRelatedWork W1980664271 @default.
- W2766321881 hasRelatedWork W1991332977 @default.
- W2766321881 hasRelatedWork W2035875009 @default.
- W2766321881 hasRelatedWork W2037400652 @default.
- W2766321881 hasRelatedWork W2050348440 @default.
- W2766321881 hasRelatedWork W2066462266 @default.
- W2766321881 hasRelatedWork W2745803145 @default.
- W2766321881 hasRelatedWork W2763351664 @default.
- W2766321881 hasRelatedWork W3158211927 @default.
- W2766321881 hasRelatedWork W3198049980 @default.
- W2766321881 hasVolume "28" @default.
- W2766321881 isParatext "false" @default.
- W2766321881 isRetracted "false" @default.
- W2766321881 magId "2766321881" @default.
- W2766321881 workType "article" @default.